Detalhe da pesquisa
1.
Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.
Signal Transduct Target Ther
; 8(1): 20, 2023 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36596779
2.
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Signal Transduct Target Ther
; 7(1): 172, 2022 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665745
3.
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.
Nat Commun
; 13(1): 3654, 2022 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35760812